ECSP055815A - Composición para el tratamiento de la infección por virus flaviviridae - Google Patents

Composición para el tratamiento de la infección por virus flaviviridae

Info

Publication number
ECSP055815A
ECSP055815A EC2005005815A ECSP055815A ECSP055815A EC SP055815 A ECSP055815 A EC SP055815A EC 2005005815 A EC2005005815 A EC 2005005815A EC SP055815 A ECSP055815 A EC SP055815A EC SP055815 A ECSP055815 A EC SP055815A
Authority
EC
Ecuador
Prior art keywords
treatment
infection
composition
virus
alkyl
Prior art date
Application number
EC2005005815A
Other languages
English (en)
Inventor
Daniel Lammarre
Lisette Lagace
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP055815A publication Critical patent/ECSP055815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Las composiciones, el uso, el artículo de fabricación y el procedimiento para el tratamiento de un mamífero infectado con un virus de la familia Flaviviridae se proporciona comprendiendo la administración al mamífero infectado de un compuesto que tiene la fórmula I: Fórmula (I)en el que,A se selecciona de: alquilo C1 - C6 y cicloalquilo C3 - C6; y B se selecciona de: fenilo o tiazolilo, ambas de las cuales están opcionalmente sustituidas con un grupo seleccionado de NH(R1) y NH(CO)R1, en el que R1 es alquilo C1 - C6; R es OH o un derivado de sulfonamida; ouna sal farmacéuticamente aceptable de la misma.
EC2005005815A 2002-10-29 2005-05-24 Composición para el tratamiento de la infección por virus flaviviridae ECSP055815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42190002P 2002-10-29 2002-10-29
US44276903P 2003-01-27 2003-01-27

Publications (1)

Publication Number Publication Date
ECSP055815A true ECSP055815A (es) 2005-08-11

Family

ID=32233460

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005815A ECSP055815A (es) 2002-10-29 2005-05-24 Composición para el tratamiento de la infección por virus flaviviridae

Country Status (13)

Country Link
US (1) US20050159345A1 (es)
EP (1) EP1558633A1 (es)
JP (1) JP2006517196A (es)
KR (1) KR20050061592A (es)
AU (1) AU2003275852A1 (es)
BR (1) BR0315781A (es)
CA (1) CA2498642A1 (es)
EA (1) EA200500610A1 (es)
EC (1) ECSP055815A (es)
MX (1) MXPA05004604A (es)
NO (1) NO20052580L (es)
PL (1) PL376409A1 (es)
WO (1) WO2004039833A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
ES2361997T3 (es) * 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
JP4902361B2 (ja) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
EP2334680A2 (en) 2008-08-20 2011-06-22 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
JP2013511562A (ja) * 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
WO2011063501A1 (en) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
JP5857053B2 (ja) 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112014030649A2 (pt) * 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos da flaviviridae vírus
PT2861604T (pt) * 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
KR101446049B1 (ko) * 2013-01-14 2014-10-01 전남대학교산학협력단 뎅기 바이러스 관련 질환의 치료 또는 예방용 조성물
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors

Also Published As

Publication number Publication date
EA200500610A1 (ru) 2005-10-27
WO2004039833A1 (en) 2004-05-13
NO20052580L (no) 2005-07-20
MXPA05004604A (es) 2005-07-13
CA2498642A1 (en) 2004-05-13
BR0315781A (pt) 2005-09-13
JP2006517196A (ja) 2006-07-20
EP1558633A1 (en) 2005-08-03
KR20050061592A (ko) 2005-06-22
AU2003275852A1 (en) 2004-05-25
PL376409A1 (en) 2005-12-27
NO20052580D0 (no) 2005-05-27
US20050159345A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
EA200970478A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
AR034448A1 (es) Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones
BR0116299A (pt) Composto, composição farmacêutica, método para o tratamento ou profilaxia de uma infecção picornaviral em um mamìfero, e, uso de um composto
CY1109497T1 (el) Παραγωγα θειοφενιου ως αντιβιοτικοι παραγοντες για λοιμωξη/μολυνση φλαβοϊου (flavivirus)
ES2259113T3 (es) Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion.
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
DE60217114D1 (de) Verbrückte bizyklische serinproteaseinhibitoren
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
HRP20020175B1 (hr) N-heterociklički derivati kao inhibitori nos
WO2010068760A3 (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
BR0305259A (pt) Inibidores de hcv ns5b polimerase
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto